Answer
In adults with non-Hodgkin lymphoma, intravenous MabThera (rituximab) has an estimated median terminal elimination half-life of 22 days (range 6.1–52 days).
Sources for this answer
- MabThera 100mg and 500mg Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 57Document updated
Sources checked